UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $10.77 Million Stock Position in Haemonetics Corporation $HAE

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Haemonetics Corporation (NYSE:HAE) by 5.8% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 143,611 shares of the medical instruments supplier’s stock after purchasing an additional 7,914 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Haemonetics were worth $10,771,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. Kemnay Advisory Services Inc. bought a new position in shares of Haemonetics during the 4th quarter worth approximately $26,000. Leonteq Securities AG bought a new stake in Haemonetics in the 4th quarter valued at $30,000. EverSource Wealth Advisors LLC lifted its holdings in Haemonetics by 2,640.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 396 shares during the last quarter. Kestra Advisory Services LLC acquired a new stake in Haemonetics during the 4th quarter valued at $34,000. Finally, Kelleher Financial Advisors bought a new position in Haemonetics during the second quarter worth $38,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on HAE. JPMorgan Chase & Co. increased their price objective on shares of Haemonetics from $62.00 to $86.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Barrington Research upped their price target on shares of Haemonetics from $95.00 to $118.00 and gave the company an “outperform” rating in a research note on Wednesday, August 19th. Robert W. Baird increased their price target on shares of Haemonetics from $96.00 to $119.00 and gave the company an “outperform” rating in a report on Friday, August 21st. Mizuho raised their price objective on shares of Haemonetics from $85.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Finally, Raymond James Financial upped their target price on Haemonetics from $105.00 to $125.00 and gave the company an “outperform” rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $99.78.

Haemonetics Trading Up 0.1%

HAE stock opened at $103.00 on Monday. The company has a debt-to-equity ratio of 1.40, a quick ratio of 1.91 and a current ratio of 3.08. The company’s 50-day simple moving average is $87.71 and its 200 day simple moving average is $71.62. Haemonetics Corporation has a 52 week low of $47.31 and a 52 week high of $109.57. The company has a market capitalization of $4.69 billion, a PE ratio of 50.49, a price-to-earnings-growth ratio of 2.06 and a beta of 0.54.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $1.08 by $0.06. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. The business had revenue of $339.38 million for the quarter, compared to analyst estimates of $327.86 million. During the same period last year, the firm earned $1.10 earnings per share. Haemonetics’s revenue for the quarter was up 5.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Haemonetics Corporation will post 5.29 earnings per share for the current year.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.